S&P 500   4,225.05 (+1.08%)
DOW   33,115.52 (+0.63%)
QQQ   352.42 (+1.27%)
AAPL   179.68 (+1.37%)
MSFT   332.01 (+1.10%)
META   273.30 (+3.24%)
GOOGL   123.39 (+0.42%)
AMZN   122.90 (+1.92%)
TSLA   208.44 (+2.21%)
NVDA   399.11 (+5.49%)
NIO   7.59 (+0.80%)
BABA   83.75 (+5.28%)
AMD   120.34 (+1.80%)
T   15.81 (+0.51%)
F   12.11 (+0.92%)
MU   69.14 (+1.38%)
CGC   0.83 (-0.60%)
GE   104.92 (+3.34%)
DIS   88.59 (+0.72%)
AMC   4.61 (+2.44%)
PFE   38.00 (-0.05%)
PYPL   63.12 (+1.82%)
NFLX   404.85 (+2.43%)
S&P 500   4,225.05 (+1.08%)
DOW   33,115.52 (+0.63%)
QQQ   352.42 (+1.27%)
AAPL   179.68 (+1.37%)
MSFT   332.01 (+1.10%)
META   273.30 (+3.24%)
GOOGL   123.39 (+0.42%)
AMZN   122.90 (+1.92%)
TSLA   208.44 (+2.21%)
NVDA   399.11 (+5.49%)
NIO   7.59 (+0.80%)
BABA   83.75 (+5.28%)
AMD   120.34 (+1.80%)
T   15.81 (+0.51%)
F   12.11 (+0.92%)
MU   69.14 (+1.38%)
CGC   0.83 (-0.60%)
GE   104.92 (+3.34%)
DIS   88.59 (+0.72%)
AMC   4.61 (+2.44%)
PFE   38.00 (-0.05%)
PYPL   63.12 (+1.82%)
NFLX   404.85 (+2.43%)
S&P 500   4,225.05 (+1.08%)
DOW   33,115.52 (+0.63%)
QQQ   352.42 (+1.27%)
AAPL   179.68 (+1.37%)
MSFT   332.01 (+1.10%)
META   273.30 (+3.24%)
GOOGL   123.39 (+0.42%)
AMZN   122.90 (+1.92%)
TSLA   208.44 (+2.21%)
NVDA   399.11 (+5.49%)
NIO   7.59 (+0.80%)
BABA   83.75 (+5.28%)
AMD   120.34 (+1.80%)
T   15.81 (+0.51%)
F   12.11 (+0.92%)
MU   69.14 (+1.38%)
CGC   0.83 (-0.60%)
GE   104.92 (+3.34%)
DIS   88.59 (+0.72%)
AMC   4.61 (+2.44%)
PFE   38.00 (-0.05%)
PYPL   63.12 (+1.82%)
NFLX   404.85 (+2.43%)
S&P 500   4,225.05 (+1.08%)
DOW   33,115.52 (+0.63%)
QQQ   352.42 (+1.27%)
AAPL   179.68 (+1.37%)
MSFT   332.01 (+1.10%)
META   273.30 (+3.24%)
GOOGL   123.39 (+0.42%)
AMZN   122.90 (+1.92%)
TSLA   208.44 (+2.21%)
NVDA   399.11 (+5.49%)
NIO   7.59 (+0.80%)
BABA   83.75 (+5.28%)
AMD   120.34 (+1.80%)
T   15.81 (+0.51%)
F   12.11 (+0.92%)
MU   69.14 (+1.38%)
CGC   0.83 (-0.60%)
GE   104.92 (+3.34%)
DIS   88.59 (+0.72%)
AMC   4.61 (+2.44%)
PFE   38.00 (-0.05%)
PYPL   63.12 (+1.82%)
NFLX   404.85 (+2.43%)
NASDAQ:BLU

BELLUS Health (BLU) Stock Forecast, Price & News

$14.61
0.00 (0.00%)
(As of 02:41 PM ET)
Compare
Today's Range
$14.57
$14.62
50-Day Range
$6.46
$14.61
52-Week Range
$6.38
$14.65
Volume
737,903 shs
Average Volume
3.05 million shs
Market Capitalization
$1.85 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.50

BELLUS Health MarketRank™ Forecast

Analyst Rating
Hold
2.40 Rating Score
Upside/​Downside
12.9% Upside
$16.50 Price Target
Short Interest
Healthy
5.64% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.93) to ($1.00) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.01 out of 5 stars

Medical Sector

1187th out of 1,980 stocks

Pharmaceutical Preparations Industry

595th out of 978 stocks


BLU stock logo

About BELLUS Health (NASDAQ:BLU) Stock

BELLUS Health, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of cough hypersensitivity and other hypersensitization disorders. Its product BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus, or chronic itch. The company was founded on June 17, 1993 and is headquartered in Laval, Canada.

Receive BLU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

BLU Stock News Headlines

BELLUS Health (NASDAQ:BLU) Hits New 52-Week High at $14.60
The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
BELLUS Health (NASDAQ:BLU) Hits New 52-Week High at $14.54
BELLUS Health Inc. (NASDAQ:BLU) Short Interest Update
Closing Bell: Bellus Health Inc up on Tuesday (BLU)
AI is Unstoppable. Now Is The Time!
AI, or Artificial Intelligence, is all the rage right now. AI technologies are empowering users in every industry to increase sales, efficiency, and productivity. It's truly a case of adapt or fail.
BELLUS Health Announces Meeting Updates
BELLUS Health (NASDAQ:BLU) Downgraded by Evercore ISI
LifeSci Capital Reaffirms Their Hold Rating on BELLUS Health (BLU)
Why BELLUS Health Stock Is Rocketing Higher Today
See More Headlines

BLU Price History

BLU Company Calendar

Last Earnings
3/21/2023
Today
6/01/2023
Next Earnings (Estimated)
8/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLU
Employees
40
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.50
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$14.75
Forecasted Upside/Downside
+12.9%
Consensus Rating
Hold
Rating Score (0-4)
2.40
Research Coverage
5 Analysts

Profitability

Net Income
$-76,080,000.00
Net Margins
-578,586.63%
Pretax Margin
-578,226.56%

Debt

Sales & Book Value

Annual Sales
$20,000.00
Price / Sales
92,627.40
Book Value
$2.91 per share

Miscellaneous

Free Float
96,152,000
Market Cap
$1.85 billion
Optionable
Not Optionable
Beta
0.18

Key Executives

  • Roberto Bellini
    President, Chief Executive Officer & Director
  • Andreas Orfanos
    Chief Operating Officer
  • Ramzi Benamar
    Chief Financial Officer
  • Denis Garceau
    Chief Scientific Officer
  • Catherine M. Bonuccelli
    Chief Medical Officer













BLU Stock - Frequently Asked Questions

Should I buy or sell BELLUS Health stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for BELLUS Health in the last twelve months. There are currently 3 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BLU shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BLU, but not buy additional shares or sell existing shares.
View BLU analyst ratings
or view top-rated stocks.

What is BELLUS Health's stock price forecast for 2023?

5 Wall Street analysts have issued 1 year price objectives for BELLUS Health's stock. Their BLU share price forecasts range from $14.75 to $20.00. On average, they predict the company's share price to reach $16.50 in the next twelve months. This suggests a possible upside of 12.9% from the stock's current price.
View analysts price targets for BLU
or view top-rated stocks among Wall Street analysts.

How have BLU shares performed in 2023?

BELLUS Health's stock was trading at $8.22 at the beginning of the year. Since then, BLU stock has increased by 77.7% and is now trading at $14.61.
View the best growth stocks for 2023 here
.

When is BELLUS Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our BLU earnings forecast
.

How were BELLUS Health's earnings last quarter?

BELLUS Health Inc. (NASDAQ:BLU) issued its earnings results on Tuesday, March, 21st. The company reported ($0.14) earnings per share (EPS) for the quarter. BELLUS Health had a negative trailing twelve-month return on equity of 24.27% and a negative net margin of 578,586.63%.

What ETFs hold BELLUS Health's stock?

ETFs with the largest weight of BELLUS Health (NASDAQ:BLU) stock in their portfolio include ProShares Ultra Nasdaq Biotechnology (BIB),

What other stocks do shareholders of BELLUS Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Big Lots (BIG), Party City Holdco (PRTY), Washington Prime Group (WPG), Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA) and Acasti Pharma (ACST).

What is BELLUS Health's stock symbol?

BELLUS Health trades on the NASDAQ under the ticker symbol "BLU."

Who are BELLUS Health's major shareholders?

BELLUS Health's stock is owned by a variety of institutional and retail investors. Top institutional investors include Pictet Asset Management SA (5.58%), Commodore Capital LP (5.19%), Perceptive Advisors LLC (3.91%), Braidwell LP (3.26%), First Light Asset Management LLC (2.38%) and FMR LLC (1.18%).

How do I buy shares of BELLUS Health?

Shares of BLU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BELLUS Health's stock price today?

One share of BLU stock can currently be purchased for approximately $14.61.

How much money does BELLUS Health make?

BELLUS Health (NASDAQ:BLU) has a market capitalization of $1.85 billion and generates $20,000.00 in revenue each year. The company earns $-76,080,000.00 in net income (profit) each year or ($0.72) on an earnings per share basis.

How can I contact BELLUS Health?

BELLUS Health's mailing address is 275 ARMAND-FRAPPIER BLVD., LAVAL A8, H7V 4A7. The official website for the company is www.bellushealth.com. The company can be reached via phone at (450) 680-4500, via email at fdesjardins@bellushealth.com, or via fax at 45-0680-4501.

This page (NASDAQ:BLU) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -